Trends in Dissolution Science: In-vitro and in-silico methods for assessing food and PPI effects

Speakers

• 

  Sanjaykumar Patel
  

  Sanjaykumar Patel

  Sanjaykumar Patel is Sr. Principal Scientist at Merck & Co., Inc. in Rahway, NJ. He has more than 22 years of experience in the pharmaceutical industry. His experience includes working on novel drug delivery formulations such as self-emulsifying drug delivery systems, amorphous solid dispersion, controlled release and gastroretentive, and parental formulation. His research interest is focused on developing predictive bio-relevant in-vitro methodologies to understand the in-vivo performance of oral and parental formulations. He has co-authored 18 scientific papers. He is an active member of AAPS and an immediate past Chair of the IVRDT (In Vitro Release and Dissolution Testing) community. He is a board member of the Society of Pharmaceutical Sciences-US Chapter in the area focusing on dissolution.

• 

  Deanna Mudie
  

  Deanna Mudie

  Deanna Mudie, Ph.D., is a Principal Scientist in Research and Development at Lonza. Her focus is on enabling bioavailability enhancing amorphous solid dispersions by developing dosage form platforms and in vitro dissolution methodologies to predict bioperformance. Deanna earned her Ph.D. in Pharmaceutical Sciences and B.S.E. in Chemical Engineering from the University of Michigan. She has seven years of pre-doctoral experience at two large pharmaceutical companies developing and manufacturing oral dosage forms from pre-clinical to commercial scale.

• 

  Christos Reppas Professor in Pharmaceutics, Department of Pharmacy, NKUA
  

  Christos Reppas

  Professor in Pharmaceutics, Department of Pharmacy, NKUA

  Christos Reppas is Professor in Pharmaceutics, Department of Pharmacy, National and Kapodistrian University of Athens (NKUA), Greece. Research interests focus to the effects of dosage form characteristics and of gastrointestinal physiology on intraluminal performance of xenobiotics and the development of in vitro tests that are predictive of the intraluminal dosage form and drug performance. He has supervised 13 completed PhD Theses. He is coauthor of more than 140 peer reviewed papers and chapters in international journals and books, two books in Biopharmaceutics and Drug Disposition and one patent. He is member of the editorial board of AAPS Journal, Journal of Pharmacy and Pharmacology, and Journal of Drug Delivery Science and Technology. He is/has been PI in several EU funded training and research programs (OrBiTo, PEARRL, COLOTAN, InPharma, AGePOP) and one COST action (UNGAP, vice-chair).

• 

  Filippos Kesisoglou
  

  Filippos Kesisoglou

  Filippos Kesisoglou is a Scientific Associate Vice President at Merck & Co., Inc., (Rahway, NJ, USA) Pharmaceutical Sciences department. Filippos has over 20 years of experience in the fields of biopharmaceutics and formulation development, pharmacokinetics, PBPK and IVIVC modeling as related to clinical, drug product development and CMC regulatory applications, including establishment of clinically relevant specifications, across modalities. He has been a key contributor to several new drug applications across therapeutic areas. He has authored/co-authored 95 manuscripts/book chapters and more than 100 conference abstracts/podium presentations/webinars in several national/international meetings in the fields of biopharmaceutics, PBPK modeling, formulation development and drug delivery. Filippos has been involved over the years in several cross-industry and academia consortia including the IQ consortium and since 2023 has joined the ICH M13 (Bioequivalence Guideline) Expert Working Group. He is currently serving as an Editor for Journal of Pharmaceutical Sciences and on the Editorial Advisory Boards for the AAPS Journal and Pharmaceutical Research. He has been elected a Fellow of the American Association of Pharmaceutical Scientists (AAPS) and of the Americal Institute for Medical and Biological Engineering (AIMBE).